Mayo Clinic’s new investment in Numares will accelerate delivery of kidney function and heart risk tests that are expected to gain 510(k) approval from the U.S. Food and Drug Administration early next year, according to the report. ‘announcement.
WHY IS IT IMPORTANT
Using algorithms to analyze multiple biomarkers to measure disease progression in patients can help doctors improve care for people with chronic diseases, including kidney and cardiovascular disease.
For nearly two decades, the company based in Woodlands, Texas, and Regensburg, Germany, has developed diagnostic tests applying artificial intelligence and advanced nuclear magnetic resonance (NMR) spectroscopy.
Numares’ tools pending FDA approval – Axinon GFR (NMR), which assesses kidney function, and Axinon Lipofit, which measures cardiac risk – could provide early intervention to slow disease progression, according to the ‘announcement.
Mayo Clinic’s convertible stock investment also supports efforts to develop AI-based diagnostic tests for other chronic diseases, such as liver disease and neurological diseases.
“This significant expansion of our longstanding collaboration with Mayo Clinic has brought us closer to our shared goal of improving patient care,” said Winton Gibbons, CEO of Numares, in the announcement.
“The new investment accelerates our development pipeline and drives research collaborations that address critical unmet medical needs with new clinical utility.”
THE GREAT TREND
Although there has been skepticism, doctors have long reported enthusiasm for the ability of AI to improve the quality of care and workflow efficiency.
A 2019 survey published by Nature found that most respondents considered advanced diagnostics as improving decision support66% answering that such tests would considerably increase the diagnostic efficiency.
The fear of AI replacing clinicians was relatively low and appears to have remained a non-issue in practice with AI deployments are accelerating in healthcare.
“AI has proven itself in many use cases and is capable of helping clinicians make critical patient care decisions,” said Sashi Padarthy, assistant vice president, Cognizant Healthcare Consulting. Health Informatics News Last year.
“AI does not replace the clinician nor does it make the decision for the clinician. AI generates insights for clinicians from data sources traditionally inaccessible to a point-of-care provider,” he said. -he declares.
“It has always been the mission of Mayo Clinic to put the needs of the patient first,” said Dr. Allan Jaffe, cardiologist and former chairman of Mayo Clinic’s Core Clinical Laboratory Services Division in the Department of laboratory medicine and pathology.
“The expanded research collaboration and financial investment in Numares will help us better understand this potentially disruptive new testing modality, develop new diagnostic tests, and enable Mayo Clinic to better serve our patients and physicians.”
Andrea Fox is the editor of Healthcare IT News.
Healthcare IT News is a HIMSS publication.